Corpus Intelligence IC Memo — UNIVERSITY OF MIAMI HOSP & CLINICS 2026-04-26 03:59 UTC
IC Memo — UNIVERSITY OF MIAMI HOSP & CLINICS
Investment Committee Memorandum | FL | 532 beds | Grade B | EBITDA uplift $174.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNIVERSITY OF MIAMI HOSP & CLINICS

CCN 100079 | MIAMI-DADE, FL | 532 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

UNIVERSITY OF MIAMI HOSP & CLINICS is a 532-bed large academic medical center in MIAMI-DADE, FL with $2.36B in net patient revenue and a 0.9% operating margin. The hospital serves a payer mix of 18.3% Medicare, 2.5% Medicaid, and 79.2% commercial.

Thesis: Undervalued. Our ML models identify $174.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.9% to 8.3% (+736bps).

Net Revenue HCRIS$2.36B
Current EBITDA COMPUTED$22.4M
Operating Margin COMPUTED0.9%
Occupancy HCRIS68.3%
Revenue / Bed COMPUTED$4.4M
Net-to-Gross HCRIS19.2%
Distress Probability ML38.7%

2. Market Context & Competitive Position

261
FL Hospitals
3.2%
State Median Margin
68
Comparable Hospitals

FL has 261 Medicare-certified hospitals with a median operating margin of 3.2%. The target's margin of 0.9% places it below the state median. Among 68 size-comparable peers (266-1064 beds), the median margin is 5.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (266-1064), prioritizing same-state peers. 68 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNIVERSITY OF MIAMI HOSP & CLI (Target)FL532$2.36B0.9%
UF HEALTH SHANDSFL994$2.24B10.4%
BAPTIST MEDICAL CENTERFL980$1.78B0.9%
TAMPA GENERAL HOSPITALFL898$1.73B-9.3%
BAPTIST HOSPITALFL948$1.71B10.8%
MEMORIAL REGIONAL HOSPITALFL838$1.45B-20.7%
LEE MEMORIAL HOSPITALFL748$1.28B17.4%
SARASOTA MEMORIAL HOSPITALFL787$1.10B8.1%
MAYO CLINIC FLORIDAFL304$1.09B21.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $174.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$49.6M+210bp18mo
Cost to Collect4.5%2.5%$47.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$46.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$28.8M+122bp9mo
Clean Claim Rate88.0%96.0%$1.5M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$49.6M
Cost to Collect
$47.3M
Denial Rate Reduction
$46.8M
A/R Days Reduction
$28.8M
Clean Claim Rate
$1.5M
Total EBITDA Uplift$174.0M
Current EBITDA$22.4M
+ RCM Uplift+$174.0M
Pro Forma EBITDA$196.4M
Current Margin0.9%
Pro Forma Margin8.3%
WC Released (1x)$90.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$34.4M$1.89B54.84x122.8%
Base (11x exit)10.0x11.0x$34.4M$2.09B60.65x127.3%
Bull Case9.0x11.0x$31.0M$2.67B86.29x143.9%
Bull (12x exit)9.0x12.0x$31.0M$2.92B94.43x148.3%
Bear Case11.0x10.0x$37.9M$1.01B26.58x92.7%
Bear (11x exit)11.0x11.0x$37.9M$1.12B29.57x96.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 68 hospitals with 266-1064 beds
  • Same-state prioritization (n=69)
  • Comp margins: P25=-6.1% / P50=5.2% / P75=18.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.